FIELD: medicine.
SUBSTANCE: invention refers to immunology, and concerns recombinant immunotoxin specific to cells expressing HER2 receptor. Recombinant immunotoxin comprises guide module in the form of antibody in scFv format, including variable domains of light and heavy chains of monoclonal humanised HER2-specific antibody interconnected by linker, and toxic module as a fragment of pseudomonal A ETA exotoxin. Guide module is presented with antibody 4D5scFv, recombinant immunotoxin comprises flexible hydrophilic hinge-like linker connecting guide module 4D5scFv with toxic ETA module, and KDEL sequence on C-end of the molecule, and recombinant immunotoxin is presented as SEQ ID NO sequence: 2.
EFFECT: using the given recombinant immunotoxin increases toxicity for cells expressing receptor HER2, and, consequently, therapeutic effectiveness.
4 cl, 6 dwg
